Here's another ripple from the Ben Venue Laboratories splashdown. Sanofi's ($SNY) Genzyme unit has recalled a batch of its leukemia drug Fludara because of worries about its sterility. The 9,380
It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...
Last week, Vertex Pharmaceuticals ($VRTX) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
Sanofi ($SNY) CEO Chris Viehbacher (photo) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme. But advances by other companies are making it
You can bet that Sanofi's ($SNY) top brass are celebrating this evening. The French drugmaker's Genzyme unit won the long-sought FDA approval for its new plant in Framingham, MA. That facility can
Genzyme flexed some market muscle Wednesday when it announced the European Medicines Agency's approval of a new U.S. facility for production of Fabrazyme. Perhaps most immediately affected by the...
Sanofi ($SNY) is looking forward to ending long-running supply problems at Genzyme. The company said Genzyme's new manufacturing plant in Framingham, MA, won approval from European regulators to
Genzyme says that, barring validation and regulatory hiccups, it expects to begin providing Fabry disease sufferers with Fabrazyme produced at its new Framingham, MA, plant beginning the first
Hospira ($HSP) shareholders claim the company didn't disclose the extent of problems at its North Carolina plant. Yet CEO Michael Ball admitted in October 2011 that the remediation job was " bigger
Ben Venue Labs is extending the timeline for remediation at an Ohio plant—and along with it the expected availability of some critical drugs currently in short supply. The company made the